2020
Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity
O'Mara A, Johnson J, Linderman J, Brychta R, McGehee S, Fletcher L, Fink Y, Kapuria D, Cassimatis T, Kelsey N, Cero C, Sater Z, Piccinini F, Baskin A, Leitner B, Cai H, Millo C, Dieckmann W, Walter M, Javitt N, Rotman Y, Walter P, Ader M, Bergman R, Herscovitch P, Chen K, Cypess A. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. Journal Of Clinical Investigation 2020, 130: 2209-2219. PMID: 31961826, PMCID: PMC7190915, DOI: 10.1172/jci131126.Peer-Reviewed Original ResearchConceptsBAT metabolic activityIntravenous glucose tolerance testGlucose tolerance testΒ3-AR agonistInsulin sensitivityTolerance testMetabolic diseasesObesity-related metabolic diseasesWhite adipose tissue lipolysisBrown adipose tissue thermogenesisOpen-label studyTotal bile acidsHuman brown fatHigher insulin sensitivityAdipose tissue lipolysisAdipose tissue thermogenesisPET/CTΒ3-adrenergic receptor agonistIntramural Research ProgramChronic pharmacological stimulationMetabolic activityMirabegron therapyMirabegron treatmentPrimary endpointSecondary endpoints
2019
Whole Body and Regional Quantification of Active Human Brown Adipose Tissue Using 18F-FDG PET/CT.
Kim K, Huang S, Fletcher LA, O'Mara AE, Tal I, Brychta RJ, Cypess AM, Chen KY, Leitner BP. Whole Body and Regional Quantification of Active Human Brown Adipose Tissue Using 18F-FDG PET/CT. Journal Of Visualized Experiments 2019 PMID: 30985755, DOI: 10.3791/58469.Peer-Reviewed Original ResearchConceptsHuman brown adipose tissueBrown adipose tissueAdipose tissueF-FDG PET/CT scanF-fluorodeoxyglucose positron emission tomographyPET/CT scansThermogenic capacityBAT thermogenic capacityActive adipose tissuePET/CTPositron emission tomographyBAT volumeTomography scanNovel therapiesAnatomical distributionCT scanMetabolic disordersPharmacological activationEmission tomographyPotential targetWhole bodyBody temperatureTissueScansRegional quantification
2018
Physiological Responses to Daily Use of Beta-Three Adrenergic Receptor Agonist, Mirabegron
O'MARA A, CYPESS A, CERO C, JOHNSON J, LINDERMAN J, LEITNER B, FLETCHER L, BRYCHTA R, KAPURIA D, MCGEHEE S, ROTMAN Y. Physiological Responses to Daily Use of Beta-Three Adrenergic Receptor Agonist, Mirabegron. Diabetes 2018, 67 DOI: 10.2337/db18-1146-p.Peer-Reviewed Original ResearchRate-pressure productNon-esterified fatty acidsBrown adipose tissueSerum non-esterified fatty acidsCold exposureWeeks of treatmentBAT metabolic activityHealthy female volunteersAdrenergic receptor agonistPET/CTΒ3-adrenergic receptor agonistDaily mirabegronCardiovascular stimulationPrimary endpointSecondary endpointsChronic treatmentBAT volumeLiver steatosisMetabolic healthPressure productTreatment optionsInsulin sensitivityPharmacotherapeutic approachesReceptor agonistAcute effectsThe Existence of Superficial Dorsocervical Brown Adipose Tissue in Women
FLETCHER L, LEITNER B, KIM K, MCGEHEE S, BRYCHTA R, CYPESS A, CHEN K. The Existence of Superficial Dorsocervical Brown Adipose Tissue in Women. Diabetes 2018, 67 DOI: 10.2337/db18-2052-p.Peer-Reviewed Original ResearchBrown adipose tissueBAT depotsAdipose tissueFascial layersInterscapular brown adipose tissueHuman brown adipose tissueBAT metabolic activityCervical brown adipose tissueLean body massDeep fascial layerPET/CTDorsocervical regionBAT activationLean massYoung subjectsHuman newbornsMetabolic diseasesMetabolic activityCold stimulationGlucose uptakeLean tissueCold exposureWomenIntermuscular regionSpecific depots